MOTS-c's first human trial is recruiting; the “exercise mimetic” claims are still unproven

The “exercise mimetic” peptide MOTS-c has a genuinely new development: the first human trial is now recruiting. The MOTS-MET study (NCT07505745) — randomized, double-blind, placebo-controlled Phase 2a — will test 12 weeks of investigational MOTS-c plus lifestyle counseling in adults with prediabetes and overweight/obesity, measuring insulin sensitivity, glucose, HbA1c, lipids, weight, and safety. But here's the part the hype skips: no completed human trial shows injected MOTS-c improves endurance, VO2max, strength, or weight. Everything else is still mice.

The regulatory reality

In July, the FDA's Pharmacy Compounding Advisory Committee voted 7–5 (with 2 abstentions) to recommend MOTS-c for the 503A bulks list — over the objections of FDA staff. That vote was nonbinding, and no approval or compounding authorization followed. Meanwhile, USADA confirms MOTS-c is prohibited in sport at all times as a metabolic modulator.

The gray-market problem

While the science catches up, gray-market sellers already market MOTS-c as an exercise shortcut. Reported side effects among buyers include palpitations, injection-site reactions, insomnia, immune reactions, and fever. An unproven peptide with real side effects and a WADA ban is a bad combination.

What to watch

MOTS-MET is the trial that could change the story — real human data, real endpoints. Until it reads out, treat every “exercise in a syringe” claim as marketing, not medicine.

Where the evidence stands

• Established: MOTS-MET (NCT07505745) is a registered recruiting Phase 2a trial; the FDA committee vote and WADA prohibition are public record.
• Preliminary: The trial has no posted results.
• Contested: Gray-market claims of endurance and fat-loss benefits.
• Absent: No completed human trial demonstrates efficacy of MOTS-c for any performance or metabolic outcome.